Scientific Support for Cryoablation for Breast Cancer
IceCure Medical is committed to the advancing research into the use of IceSense3 cryoablation for breast cancer. We believe it is a viable alternative to surgery for the treatment of some breast cancers.
We are currently enrolling patients in the landmark, multi-center ICE3 trial, where certain breast cancers will be cryoablated, then followed. No Surgery. We also support investigator-initiated studies at various academic institutions around the globe, including Kameda and St. Johns.
Because it utilizes the more advanced IceSense3 cryoablation system with low, stable, cryo temperatures, ICE3 has the potential to completely ablate tumors up to 1.5 cm.
Our clinical trial will recruit and follow-up on women aged 65 years or older diagnosed with luminal A breast carcinoma whose tumors measure less than 1.5 centimeters in diameter. These patients will also receive adjunctive therapy based on local standards of care and will be treated with cryoablation for Breast Cancer.
The trial was crafted by a diverse and esteemed scientific advisory board and will be conducted at 20 carefully selected sites throughout the United States and utilize IceSense3 consoles already installed for the treatment of fibroadenomas. As a market leader in cryoablation treatment for breast cancer and of fibroadenomas, we will utilize our resources to provide clinical and technological support to sites.
The benefits of utilizing Cryoablation for Breast Cancer to treat breast disease versus the historical treatment of excision or mastectomy are numerous. Cryoablation can be performed in a physician’s office with use of local anesthetic and ultrasound. Additionally, because no tissue is removed, there is minimal cosmetic impact with little to no scarring or permanent disfigurement. Further, cryoablation is an economically sound alternative to costly surgery.
Simmons, R. Abstract Title: A Phase II Trial Exploring the Success of Cryoablation Therapy in the Treatment of Invasive Breast Carcinoma: Results from ACOSOG (Alliance) Z1072.
Sabel MS, Su G, Griffith KA et al. Rate of Freeze Alters the Immunologic Response After Cryoablation of Breast Cancer. Annals of Surgical Oncology; Vol.17 Issue 4, Apr. 2009.
Trial Locations for Cryoablation for Breast Cancer
The following locations are actively recruiting patients for the ICE3 trial.
Laguna Hills, CA 92653
Principal Investigator: Lisa Curcio, MD
Northeast Medical Group
Trumbull, Connecticut 06611
Principal Investigator: Andrew Kenler, MD
Dalton Surgical Group
Dalton, GA 30720
Principal Investigator: Eric Manahan, MD
Indiana University-Simon Cancer Center
Indianapolis, IN 46202
Principal Investigator: Linda Han, MD
Comprehensive Breast Care
Troy, MI 48085
Principal Investigator: Linsey Gold, MD
Karmanos Cancer Institute
Detroit, MI 48201
Principal Investigator: Hussein Aoun, MD
Regional Medical Imaging
Flint, Michigan, 48507
Principal Investigator: Randy Hicks, MD
CentraState Medical Center
Freehold, New Jersey, 07728
Principal Investigator: Kenneth Tomkovich, MD
Breast Specialty Care
Albuquerque, NM 87114
Principal Investigator: Susan Seedman, MD
Beth Israel Comprehensive Cancer Center
New York, NY 10011
Principal Investigator: Susan Boolbol, MD/ Sarah Cate, MD
Columbia University Medical Center
New York, NY 10032
Principal Investigator: Margaret Chen, MD
Weill Cornell Medicine
New York, NY 10065
Principal Investigator: Rache Simmons, MD
Montefiore-Einstein Center for Cancer Care
Bronx, NY 10461
Principal Investigator: Sheldon Feldman, MD
Cincinnati Breast Surgeons Inc.
Cincinnati, Ohio, 45227
Principal Investigator: Karen S Columbus, MD
Thomas Jefferson University
Philadelphia, PA 19107
Principal Investigator: Alexander Sevrukov, MD
The West Clinic
Germantown, TN 38138
Principal Investigator: Richard Fine, MD
Complete Breast Care
Plano, TX 75075
Principal Investigator: Beth Anglin, MD FACS
You can read more about the cryoablation for breast cancer trial by clicking here.
To contact any of these facilities, please visit our Find Treatment page.